Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BMO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BMO and 80,000+ other tickers.
See exactly how BMO's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMO and 80,000+ other tickers.
Bank of Montreal engages in the provision of diversified financial services primarily in North America. The company operates through Canadian P&C, U.S P&C, BMO Wealth Management, and BMO Capital Markets segments. It’s personal banking products and services include deposits, home lending, consumer credit, small business lending, credit cards, cash management, financial and investment advice, and other banking services; and commercial banking products and services comprise various of financing options and treasury and payment solutions, as well as risk management products. It also offers…
Shares of Bank of Montreal (TSE: BMO - Get Free Report) (NYSE: BMO) have received an average recommendation of "Hold" from the thirteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating
Shares of Bank Of Montreal (NYSE: BMO - Get Free Report) (TSE: BMO) have earned an average recommendation of "Hold" from the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have assigned a buy
Executive with three decades of life sciences financing and M&A experience joins the board as Lobe advances L-130 in anxiety and cluster headache and S-100 in sickle cell disease VANCOUVER, BC / ACCESS Newswire / October 14, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today announced the appointment of Annette Grimaldi to its Board of Directors.
Earl Davis, BMO Global Asset Management fixed income and money markets head, says it's inevitable that 30-year treasury bond yields will cross 6%. He says it could happen this month and explains the call on "Bloomberg Surveillance.
BMO and Mastercard have launched a new embedded commercial payments capability that can be integrated into participating enterprise software platforms in Canada and the United States, BMO said in a Thursday (Oct. 1) press release.